15861-30-0

Basic information

• Product Name: 2,3-DIHYDRO-1H-INDOLE-5-CARBOXYLIC ACID
• Synonyms: 2,3-DIHYDRO-1H-INDOLE-5-CARBOXYLIC ACID;INDOLINE-5-CARBOXYLIC ACID;Indoline-5-carboxylic acid ,97%;2,3-Dihydro-1H-indole-5-carboxylic acid methyl ester;1H-Indole-5-carboxylic acid, 2,3-dihydro-;5-carboxylindoline
• CAS NO: 15861-30-0
• Molecular Formula: C₉H₉NO₂
• Molecular Weight: 163.17
• Mol File: 15861-30-0.mol

Chemical Properties

• Boiling Point: 369.037 °C at 760 mmHg
• Flash Point: 176.987 °C
• Appearance: /
• Density: 1.284 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.611
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 2,3-DIHYDRO-1H-INDOLE-5-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-DIHYDRO-1H-INDOLE-5-CARBOXYLIC ACID(15861-30-0)
• EPA Substance Registry System: 2,3-DIHYDRO-1H-INDOLE-5-CARBOXYLIC ACID(15861-30-0)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• Hazardous Substances Data: 15861-30-0(Hazardous Substances Data)

Usage

Chemical Properties

Light yellow solid

InChI:InChI=1/C9H9NO2/c11-9(12)7-1-2-8-6(5-7)3-4-10-8/h1-2,5,10H,3-4H2,(H,11,12)

Upstream product

• 1670-81-1 1H-Indole-5-carboxylic acid 
• 141452-01-9 2,3-dihydro-1H-indole-5-carboxylic acid methyl ester 
• 1011-65-0 5-methoxycarbonylindole 

Downstream Products

• 142165-63-7 1-carbobenzoxy-5-carboxyindoline 
• 153247-93-9 1-acetylindoline-5-carboxylic acid 
• 156578-52-8 5-Chlorocarbonyl-2,3-dihydro-indole-1-carboxylic acid benzyl ester 
• 142165-67-1 (S)-2-[(1-Benzyloxycarbonyl-2,3-dihydro-1H-indole-5-carbonyl)-amino]-hexanedioic acid dimethyl ester 
• 142165-64-8 (S)-2-[(1-Benzyloxycarbonyl-2,3-dihydro-1H-indole-5-carbonyl)-amino]-pentanedioic acid diethyl ester 
• 339007-88-4 1-(tert-butoxycarbonyl)indoline-5-carboxylic acid 
• 141452-01-9 2,3-dihydro-1H-indole-5-carboxylic acid methyl ester 

Relevant articles and documents

Cyclin-dependent kinase inhibitors and application thereof

The invention relates to compounds used as cyclin-dependent kinase inhibitors and application thereof, belonging to the field of medical chemistry. Specifically, the invention provides the compound asshown in a formula I which is described in the specification, or isomers, pharmaceutically acceptable salts, solvates, crystals or prodrugs thereof, preparation methods thereof, pharmaceutical compositions containing the compounds, and application of the compounds or the compositions to treatment of cancer, tissue hyperplasia diseases or inflammatory diseases. The compounds of the invention havegood inhibitory activity to CDK7 and are highly expected to be developed into a therapeutic agent for cancer, tissue hyperplasia diseases and inflammatory diseases.

Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5- carboxamide, an agonist of the α7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: Synthesis and structure-activity relationship

N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide (14, PHA-543,613), a novel agonist of the α7 neuronal nicotinic acetylcholine receptor (α7 nAChR), has been identified as a potential treatment of cognitive deficits in schizophrenia. Compound 14 is a potent and selective a7 nAChR agonist with an excellent in vitro profile. The compound is characterized by rapid brain penetration and high oral bioavailability in rat and demonstrates in vivo efficacy in auditory sensory gating and, in an in vivo model to assess cognitive performance, novel object recognition.

A new photolabile linker for the photoactivation of carboxyl groups

A new photolabile linker enabling nucleophilic cleavage of a carboxyl functionality upon irradiation with UV light (>290 nm) was developed. When the photocleavage is carried out in the presence of primary or secondary amines, amides are obtained in high yields and purifies, while the intramolecular version of this reaction leads to heterocycles via a cyclorelease mechanism.